OrsoBio is developing novel approaches to treat patients living with obesity and associated metabolic disorders, including diabetes, MASH, and more.
Mitochondrial protonophores to increase energy expenditure and improve metabolic and cardiovascular health in patients living with obesity and associated metabolic conditions
Liver X Receptor (LXR) inhibition to improve plasma triglycerides, cholesterol, and hepatic steatosis in patients with severe hypertriglyceridemia and MASH
ACMSD inhibition to augment NAD+ biosynthesis and improve mitochondrial function in patients with metabolic and inflammatory liver and/or kidney disorders
Mitochondrial protonophores to increase energy expenditure and improve metabolic and cardiovascular health in patients with lipodystrophies and other metabolic disorders
Mitochondrial protonophore TLC-6740
Mitochondrial protonophore TLC-1180
Mitochondrial protonophore TLC-1235
LXR inverse agonist TLC-2716
ACC2 inhibitor TLC-3595
ACMSD inhibitor
OrsoBio’s therapies target fundamental pathways of energy metabolism, and our team of physicians and scientists draw on decades of drug development experience.
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.
